Assessment of Treatment with Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial

Ghassan K. Abou-Alfa, Qian Shi, Jennifer J. Knox, Andreas Kaubisch, Donna Niedzwiecki, James Posey, Benjamin R. Tan, Petr Kavan, Rakesh Goel, Philip E. Lammers, Tanios S. Bekaii-Saab, Vincent C. Tam, Lakshmi Rajdev, Robin K. Kelley, Imane El Dika, Tyler Zemla, Ryan I. Potaracke, Jennifer Balletti, Anthony B. El-Khoueiry, James J. HardingJennifer M. Suga, Lawrence H. Schwartz, Richard M. Goldberg, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O'Reilly, Alan P. Venook

Research output: Contribution to journalArticle

11 Scopus citations

Fingerprint Dive into the research topics of 'Assessment of Treatment with Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences